MAPK1 and melanoma: The ability of using ERK shRNAs to not only kill melanoma cells, but to block emergence of treatment resistant clones likely involves not only reductions in levels of phospho-ERKs, but also in upstream reductions in BRAF, CRAF and phospho-MEK thereby interrupting a feedback loop critical to melanoma survival.